---
document_datetime: 2024-12-03 17:19:34
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/bevespi-aerosphere-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: bevespi-aerosphere-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.9682447
conversion_datetime: 2025-12-23 01:56:15.565493
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Bevespi Aerosphere

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0021               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                      | 02/12/2024                          |                                             | Labelling and PL                 |           |
| IA/0020              | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites | 02/08/2024                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |                 |                                                                                                                                                                                                 |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0019/G | This was an application for a group of variations. B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.d.1.g - Change in the specification parameters and/or limits of the finished product - Addition or replacement (excluding biological or immunological product) of a specification parameter wit its corresponding test method as a result of a safety or quality issue A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including | 22/02/2024 | Annex II and PL | Annex II has been updated as follows: â€¢ Delete AstraZeneca GmbH, Wedel, Germany from the list of the manufacturers responsible for batch release; Package Leaflet has been updated accordingly. |

<div style=\"page-break-after: always\"></div>

| PSUSA/10739 /202304   | Periodic Safety Update EU Single assessment - glycopyrronium bromide / formoterol                                                                                                                                                              | 30/11/2023   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0017                | Renewal of the marketing authorisation.                                                                                                                                                                                                        | 20/07/2023   | 15/09/2023 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Bevespi Aerosphere in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/10739 /202204   | Periodic Safety Update EU Single assessment - glycopyrronium bromide / formoterol                                                                                                                                                              | 01/12/2022   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                |
| N/0015                | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                               | 13/07/2022   | 15/09/2023 | PL                               |                                                                                                                                                                                                                                                                                  |
| N/0013                | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                               | 11/05/2022   | 15/09/2023 | Labelling and PL                 |                                                                                                                                                                                                                                                                                  |
| IA/0014               | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                  | 24/03/2022   | n/a        |                                  |                                                                                                                                                                                                                                                                                  |
| PSUSA/10739 /202104   | Periodic Safety Update EU Single assessment - glycopyrronium bromide / formoterol                                                                                                                                                              | 02/12/2021   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                |
| IA/0012/G             | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer | 26/07/2021   | n/a        |                                  |                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                     | deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer   |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10739 /202010 | Periodic Safety Update EU Single assessment - glycopyrronium bromide / formoterol                                                                                                                                                                                                                                                            | 10/06/2021 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                 |
| IA/0009             | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                   | 02/12/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                   |
| PSUSA/10739 /202004 | Periodic Safety Update EU Single assessment - glycopyrronium bromide / formoterol                                                                                                                                                                                                                                                            | 26/11/2020 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                 |
| II/0006             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                            | 17/09/2020 | 16/07/2021 | SmPC, Annex II, Labelling and PL | Urinary tract infection (UTI) has been commonly reported in several studies including glycopyrronium. Urinary tract infection is an expected ADR for other inhaled LAMA as well. UTI is therefore included as an adverse drug reaction in the SmPC, section 4.8 with the frequency common. The Patient Leaflet, section 4 is updated accordingly. |
| IA/0008             | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                   | 28/07/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10739 /201910   | Periodic Safety Update EU Single assessment - glycopyrronium bromide / formoterol                                                                                                                                                                                                                                                                                                                                                                                                                | 14/05/2020   | n/a        |                                  | PRAC Recommendation - maintenance   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------------------|
| IB/0005               | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                        | 15/04/2020   | 16/07/2021 | SmPC                             |                                     |
| IB/0004/G             | This was an application for a group of variations. B.I.a.1.i - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new site of micronisation B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                       | 08/04/2020   | n/a        |                                  |                                     |
| PSUSA/10739 /201904   | Periodic Safety Update EU Single assessment - glycopyrronium bromide / formoterol                                                                                                                                                                                                                                                                                                                                                                                                                | 31/10/2019   | n/a        |                                  | PRAC Recommendation - maintenance   |
| IB/0001/G             | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 10/05/2019   | 23/04/2020 | SmPC, Annex II, Labelling and PL |                                     |

<div style=\"page-break-after: always\"></div>

| B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes C.I.12 - Inclusion or deletion of black symbol and explanatory statements for medicinal products in the list of medicinal products that are subject to additional monitoring   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|